Interleukin-17A induces extracellular matrix protein expression in osteoblastic ROS17/2.8 cells

Interleukin (IL)-17 plays an important role in many autoimmune and inflammatory diseases. We recently demonstrated the various direct and indirect effects of IL-17A on osteoclastogenesis. However, the effect of IL-17A on bone matrix formation by osteoblasts is unclear. Therefore, we examined the effect of IL-17A on IL-17 receptor (IL-17R), extracellular matrix protein (ECMP), and cyclooxygenase (COX) expression; prostaglandin (PG) E ₂ production; alkaline phosphatase (ALPase) activity; and mineralized nodule formation in osteoblastic ROS17/2.8 cells. We also examined the indirect effect of PGE ₂ on IL-17-induced ECMP expression using NS398, a specific inhibitor of COX-2 activity. Cells were cultured with 0 (control), 1, 10, or 100 ng/mL IL-17A in the presence or absence of 50 ng/mL neutralizing anti-IL-17A antibodies or 1 μM NS398. IL-17RA, IL-17RC, type I collagen, bone sialoprotein (BSP), osteocalcin, osteopontin, COX-1, and COX-2 expression was examined by real-time PCR and Western blotting. PGE ₂ production was examined by ELISA. The expression of IL-17RA, type I collagen, BSP, osteocalcin, osteopontin, and COX-2, and PGE ₂ production were increased significantly in the presence of IL-17A, whereas the expression of IL-17RC and COX-1, cell proliferation, ALPase activity, and mineralized nodule formation were unaffected. Anti-IL-17 antibodies blocked IL-17Ainduced ECMP expression. NS398 blocked IL-17A-induced PGE ₂ production, but it did not affect IL-17Ainduced ECMP expression. These results suggest that IL-17A stimulates ECMP expression via IL-17RC and/or IL-17A-induced IL-17RA in osteoblasts; however, mineralized nodule formation by the cells was unaffected by the addition of IL-17A. Furthermore, our results indicate that the stimulatory effect of IL-17A on ECMP expression is independent of the indirect effect of IL-17A-induced PGE ₂.